There were more than 30 different companies in the psychedelic space present at the inaugural Benzinga Psychedelics Capital Conference on Tuesday. But, Enveric is one of the only ones that offer investors exposure to both the psychedelic and cannabis space. Enveric Biosciences Inc ENVB is a biotech company headquartered in Naples, Florida.
Dr. Joseph Tucker, CEO of Enveric, spoke at the conference about the company’s unique approach to drug discovery and development.
Last October, Enveric announced its “psybrary,” a library of psychedelic molecules that have the potential to treat a number of different diagnoses, including cancer-related illnesses.
Today's Best Finance Deals
“Because we have so many of these molecules, it would take us too much time to go through all of them,” Tucker said. “We’ve had to bring in AI.”
Its PsyAI technology combs through millions of molecules to find the ones that have the most potential.
In addition to Enveric’s psychedelic compounds, the company has developed its own CBD molecule that targets the effects of chemotherapy. Phase 1 trials are set to begin for the CBD molecule in 2022.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
